Skip to main content

Table 1 Patient characteristics

From: Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy

   

n = 108

Age

Median (range)

 

65 (34–83)

Gender (male/female)

  

58/50

Performance status

(0, 1, 2, 3)

 

(91, 16, 1, 0)

Body mass indexa

  

23.3 (13.7–36.9)

Primary tumor site

   
 

Colon/rectum

 

75/33

 

Right-sided/left-sided

 

51/57

Residual of primary tumor

  

17 (15.7%)

History of liver resection for metastasis

  

27 (25.0%)

Number of liver metastasisa

  

5 (0–28)

Target lesion of chemotherapy

 

Primary tumor

 

19 (17.6%)

 

Lymph node

 

28 (25.9%)

 

Peritoneum

 

18 (16.7%)

 

Lung

 

29 (26.9%)

 

Liver

 

43 (39.8%)

KRAS status

Wild

 

67 (62.0%)

First line chemotherapy

FOLFOX/FOLFIRI

 

30/78

Add-on targeting agent

VEGFR

 

41 (38.0%)

 

EGFR

 

38 (35.1%)

 

None

 

29 (26.9%)

Preoperative statusa

 

White blood cell

(mm3)(mm3)

6000 (3400–9950)

 

Neutrophil

(mm3)(mm3)

3887 (1659–3750)

 

Lymphocyte

(mm3)(mm3)

1352 (512–2195)

 

Albumin

(g/dl)

3.8 (2.4–4.7)

 

Total bilirubin

(mg/dl)

0.46 (0.19–3.82)

 

Aspartate aminotransferase

(IU/L)

23 (12–203)

 

Lactate dehydrogenase

(IU/L)

196 (21–1949)

 

Blood urea nitrogen

(mg/dL)

13.7 (4.7–27.7)

 

Creatinine

 

0.68 (0.42–1.59)

 

C-reactive protein

(mg/dL)

0.45 (0.1–8.94)

 

Carcinoembryonic antigen

(mg/L)

18.0 (4.7–65.3)

 

CA19-9

(mg/L)

35.7 (6.5–129.4)

  1. Data express median with internal quadorant range
  2. aMedian with range